BioStock: Rights issue to give Biosergen first in-human efficacy data

Recently having closed a partnership deal with Alkem, Biosergen is advancing its antifungal drug candidate BSG005 through clinical studies. With Alkem later financing phase II and III studies, Biosergen is now carrying out a SEK 40.5 million rights issue to fund a first-in-patient safety and efficacy study in a patient group with no other treatment option.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/03/rights-issue-to-give-biosergen-first-in-human-efficacy-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se